In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.

Simple item page
dc.contributor.authorTünger, Alperen_US
dc.contributor.authorAydemir, Söhreten_US
dc.contributor.authorUluer, Serveten_US
dc.contributor.authorCilli, Ferihaen_US
dc.date.accessioned2004-12-18en_US
dc.date.accessioned2009-05-27T07:40:02Z
dc.date.available2004-12-18en_US
dc.date.available2009-05-27T07:40:02Z
dc.date.issued2004-12-18en_US
dc.description.abstractBACKGROUND & OBJECTIVES: Since the incidence of vancomycin- and methicillin-resistant Gram-positive infections continue to increase, novel antimicrobials such as linezolid and streptogramin may provide new options to treat patients. The aim of this study was to investigate in vitro susceptibility of Enterococcus faecium resistant to glycopeptides, coagulase negative staphylococci and S. aureus resistant to methicillin isolated mainly from blood and also rectal swab cultures of patients against quinupristin/dalfopristin and linezolid. METHODS: The in vitro susceptibility to linezolid and quinupristin/dalfopristin for a total of 332 isolates of Gram-positive cocci [127 methicillin-resistant Staphylococcus aureus, 109 methicillin-resistant coagulase negative staphylococci (71 S. epidermidis, 38 S. haemolyticus) and 96 vanA genotype vancomycin-resistant Enterococcus faecium] was investigated by E test. RESULTS: All MRSA and MRCoNS isolates were susceptible to linezolid (MICs < 4.0 mg/l). Ninety per cent of VRE isolates were inhibited by linezolid at concentration of 2.0 mg/l and presented similar activities to quinupristin/dalfopristin. MICs for quinupristin/dalfopristin against staphylococci were also low (MIC(90) = 1.0 mg/l for both MRSA and MRCoNS isolates). INTERPRETATION & CONCLUSION: The results of the present study demonstrated that quinupristin/ dalfopristin and linezolid, have good in vitro activity against MRSA, MRCoNS and vancomycin resistant E. faecium in Turkey. These drugs could be promising therapeutic options in an era of rapidly growing antibiotic resistance in all parts of world.en_US
dc.description.affiliationDepartment of Microbiology and Clinical Microbiology, Ege University Medical Faculty, 35100 Izmir, Turkey. tunger@med.ege.edu.tren_US
dc.identifier.citationTünger A, Aydemir S, Uluer S, Cilli F. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci. Indian Journal of Medical Research. 2004 Dec; 120(6): 546-52en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/21601
dc.language.isoengen_US
dc.source.urihttps://icmr.nic.in/ijmr/ijmr.htmen_US
dc.subject.meshAcetamides --pharmacologyen_US
dc.subject.meshAnti-Bacterial Agents --pharmacologyen_US
dc.subject.meshAnti-Infective Agents --pharmacologyen_US
dc.subject.meshDrug Resistance, Multiple, Bacterialen_US
dc.subject.meshEnterococcus faecium --drug effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshOxazolidinones --pharmacologyen_US
dc.subject.meshStaphylococcus --drug effectsen_US
dc.subject.meshTurkeyen_US
dc.subject.meshVirginiamycin --analogs & derivativesen_US
dc.titleIn vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Medical Research